• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Kamada Ltd.

    3/5/25 12:46:58 PM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KMDA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 8)


    Kamada Ltd.

    (Name of Issuer)


    Ordinary Shares, par value NIS 1.0 per share

    (Title of Class of Securities)


    M6240T109

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    M6240T109


    1Names of Reporting Persons

    Gov Financial Holdings Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    ISRAEL
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,455,459.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,455,459.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,455,459.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.53 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  * Gov Financial Holdings Ltd. ("Gov") is wholly-owned by Mr. Leon Recanati, who exercises sole voting and investment power over the shares held by Gov. ** Calculated based on 57,505,031 ordinary shares of the Issuer outstanding as of December 31, 2024.


    SCHEDULE 13G

    CUSIP No.
    M6240T109


    1Names of Reporting Persons

    Insight Capital Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    ISRAEL
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,346,335.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,346,335.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,346,335.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.34 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  * Insight Capital Ltd. ("Insight") is wholly-owned by Mr. Leon Recanati, who exercises sole voting and investment power over the shares held by Insight. ** Calculated based on 57,505,031 ordinary shares of the Issuer outstanding as of December 31, 2024.


    SCHEDULE 13G

    CUSIP No.
    M6240T109


    1Names of Reporting Persons

    Leon Recanati
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    ISRAEL
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    687,645.00
    6Shared Voting Power

    2,801,794.00
    7Sole Dispositive Power

    687,645.00
    8Shared Dispositive Power

    2,801,794.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,489,439.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.07 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  * Mr. Recanati directly holds 631,145 ordinary shares of the Issuer and options to purchase 56,500 ordinary shares of the Issuer currently exercisable or exercisable within 60 days of December 31, 2024. In addition, Mr. Recanati beneficially owns 1,455,459 ordinary shares of the Issuer through Gov and 1,346,335 ordinary shares of the Issuer through Insight, both of which are wholly-owned by Mr. Leon Recanati. ** Calculated based on 57,505,031 ordinary shares of the Issuer outstanding as of December 31, 2024.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Kamada Ltd.
    (b)Address of issuer's principal executive offices:

    2 Holzman St., Science Park, P.O. Box 4081, Rehovot, 7670402, Israel
    Item 2. 
    (a)Name of person filing:

    Gov Financial Holdings Ltd. Insight Capital Ltd. Leon Recanati
    (b)Address or principal business office or, if none, residence:

    27 Yoav St. 69081, Israel
    (c)Citizenship:

    Israel
    (d)Title of class of securities:

    Ordinary Shares, par value NIS 1.0 per share
    (e)CUSIP No.:

    M6240T109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Gov Financial Holdings Ltd. 1,455,459 Ordinary Shares Insight Capital Ltd. 1,346,335 Leon Recanati 3,489,439 Ordinary Shares
    (b)Percent of class:

    Gov Financial Holdings Ltd. 2.53%* Insight Capital Ltd. 2.34%* Leon Recanati 6.07%* * Calculated based on 57,505,031 ordinary shares of the Issuer outstanding as of December 31, 2024.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Item 5 of each cover page.

     (ii) Shared power to vote or to direct the vote:

    See Item 6 of each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See Item 7 of each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See Item 8 of each cover page. * Calculations are based on 57,505,031 Ordinary Shares of the Issuer outstanding as of December 31, 2024.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Gov Financial Holdings Ltd.
     
    Signature:/s/ Leon Recanati
    Name/Title:Leon Recanati/Chairman and CEO
    Date:03/05/2025
     
    Insight Capital Ltd.
     
    Signature:/s/ Leon Recanati
    Name/Title:Leon Recanati/Chairman and CEO
    Date:03/05/2025
     
    Leon Recanati
     
    Signature:/s/ Leon Recanati
    Name/Title:Leon Recanati
    Date:03/05/2025
    Exhibit Information

    Exhibit 99.1 Joint Filing Agreement, dated March 5, 2025

    Get the next $KMDA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KMDA

    DatePrice TargetRatingAnalyst
    3/21/2025$15.00Buy
    The Benchmark Company
    7/3/2024$18.00Buy
    Stifel
    More analyst ratings

    $KMDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    The Benchmark Company initiated coverage on Kamada with a new price target

    The Benchmark Company initiated coverage of Kamada with a rating of Buy and set a new price target of $15.00

    3/21/25 8:11:15 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel initiated coverage on Kamada with a new price target

    Stifel initiated coverage of Kamada with a rating of Buy and set a new price target of $18.00

    7/3/24 7:31:15 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance

    2026 Guidance Represents Year-Over-Year Increase of 13% in Revenues and 23% in Adjusted EBITDA Based on Mid-Point of 2025 Annual Guidance2026 Annual Guidance is Based Solely on Continued Organic GrowthCompany Continues to Focus on Securing New Business Development and M&A Transactions to Accelerate Long-Term Profitable Growth Kamada Affirms 2025 Guidance of $178 Million - $182 Million in Revenues and $40 Million - $44 Million of Adjusted EBITDA2025 Year-End Cash of Approximately $75 Million REHOVOT, Israel and HOBOKEN, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for ra

    1/7/26 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada Announces a $10-$14 Million Extension of Canadian Supply Tender

    Company Awarded Extension to Existing Supply Tender Relating to its Portfolio of Four Specialty Plasma-Derived ProductsSupply Extension Secures Ongoing Sales of Approximately $5.0-$7.0 Million Per Year for the Period Between Q2-26 and Q1-28Kamada Reiterates its 2025 Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 MillionKamada Projects Double-Digit Growth in Revenues and Profitability in 2026; Detailed Guidance to be Provided in January 2026 REHOVOT, Israel, and HOBOKEN, N.J., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare

    12/18/25 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026

    Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint Kamada Continues to Supply GLASSIA®, its AAT-IV Treatment, Marketed Internationally Including in the U.S. and Canada Through a License Agreement with TAKEDAKamada Reiterates its 2025 Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million  Kamada Projects Double-Digit Growth in Revenues and Profitability in 2026; Detailed Guidance to be Provided in January 2026  Company is Focused on Pursuing Business Development Opportunities to Support Continued Long-Term GrowthManagement to Ho

    12/8/25 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    SEC Filings

    View All

    SEC Form 6-K filed by Kamada Ltd.

    6-K - KAMADA LTD (0001567529) (Filer)

    1/7/26 7:00:48 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Kamada Ltd.

    6-K - KAMADA LTD (0001567529) (Filer)

    12/18/25 7:00:02 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Kamada Ltd.

    6-K - KAMADA LTD (0001567529) (Filer)

    12/10/25 9:15:01 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Financials

    Live finance-specific insights

    View All

    Kamada Announces Discontinuation of its Phase 3 Inhaled AAT Clinical Trial; Reiterates 2025 Full-Year Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2026

    Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically Significant Benefit in its Primary Endpoint Kamada Continues to Supply GLASSIA®, its AAT-IV Treatment, Marketed Internationally Including in the U.S. and Canada Through a License Agreement with TAKEDAKamada Reiterates its 2025 Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million  Kamada Projects Double-Digit Growth in Revenues and Profitability in 2026; Detailed Guidance to be Provided in January 2026  Company is Focused on Pursuing Business Development Opportunities to Support Continued Long-Term GrowthManagement to Ho

    12/8/25 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

    Third Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up 35% Year-over-Year Positive Outlook for Remainder of 2025 Based on the Company's Diverse Product Portfolio Supports Full-Year Revenue Guidance of $178 Million-$182 Million and Adjusted EBITDA of $40 Million-$44 Million Generated $17.9 Million of Cash from Operations During First Nine Months of 2025; as of September 30, 2025, had $72.0 Million of Available CashCompany Continues to Focus on Advancing Business Development Opportunities to Support Continued Long-Term Annual Doub

    11/10/25 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025

    REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and nine months ended September 30, 2025, prior to the open of the U.S. financial markets on Monday, November 10, 2025. Kamada management will host an investment community conference call on Monday, November 10, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties

    11/3/25 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Leadership Updates

    Live Leadership Updates

    View All

    Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds

    Funding Strengthens Kamada's Financial Position, Supporting its Growth Plans and the Pursuit of Strategic Business Development OpportunitiesAppointment of Two New Independent Directors to its Board: Professor Benjamin Dekel and Mr. Assaf Itshayek REHOVOT, Israel and HOBOKEN, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced shareholder approval and planned closing of the previously announced $60 million private placement (the "Private Placement") with FIMI Op

    8/30/23 7:00:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary

    REHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))) ("Kamada" or the "Company"), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that following the recently announced $60 million private placement with the FIMI Opportunity Funds, which is expected to contribute to accelerating the growth of its existing business and allow the Company to pursue compelling business development opportunities, Chief Financial Officer (CFO), Chaime Orlev, who had previously planned to transition out of h

    5/24/23 7:05:00 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KMDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kamada Ltd.

    SC 13G/A - KAMADA LTD (0001567529) (Subject)

    11/14/24 6:21:51 AM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Kamada Ltd. (Amendment)

    SC 13G/A - KAMADA LTD (0001567529) (Subject)

    2/14/24 5:04:02 PM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Kamada Ltd. (Amendment)

    SC 13G/A - KAMADA LTD (0001567529) (Subject)

    2/12/24 12:41:57 PM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care